artificial intelligence Archives - Medical Design Sourcing

HeartBeam partners with Samsung to boost at-home cardiac care

HeartBeam has announced a strategic alliance agreement (SAA) with global tech giant Samsung.

The alliance, announced today, builds upon an existing SAA between Samsung and Livmor, whose assets HeartBeam acquired earlier this year.

Livmor created the FDA-cleared wearable Halo atrial fibrillation detection system — an FDA-cleared, Samsung-Galaxy-watch-based arrhythmia detection tool. Meanwhile, HeartBeam recently secured a pivotal patent related to artificial intelligence capabilities for its AIMIGo system — a personal, portable vector electrocardiogram (VECG) system. Also, this month, HeartBeam submitted AIMIGo for FDA 510(k) clearance.

This collaborative venture between HeartBeam and Samsung will explore opportunities to leverage HeartBeam’s proprietary technology and expertise in cardiac symptom assessment and monitoring. The two companies think their technologies could boost the standard of cardiac diagnostic capabilities.

HeartBeam’…

PsychoGenics’ SmartCube prompts a reevaluation of CNS drug discovery

SmartCube integrates behavioral neurobiology, robotics and computer vision to process and analyze large temporal and vector-based datasets. This platform uses proprietary bioinformatics and probabilistic causal inference algorithms to explore compounds’ potential to treat psychiatric disorders. [Image courtesy of PsychoGenics]

In an era of rapid AI progress, the quest to pioneer the first AI-developed drug candidates has led to an increasing number of these drug candidates entering clinical trials. One contender is ulotaront, an antipsychotic drug, that fared well in a phase 3 schizophrenia study published in NEJM in 2020. The trace amine-associated receptor 1 agonist has entered phase 2/3 studies to test its potential in generalized anxiety disorder and as an adjunctive therapy for major depressive disorder treatment.

“Not only is this the first drug discovered using machine learning that’s th…

WHO warns of generative AI’s potential for harm in healthcare

The World Health Organization (WHO) yesterday warned of the risks from using AI-generated large language model (LLM) tools in healthcare.

LLMs like OpenAI’s ChatGPT and Google Bard have the potential to make healthcare more efficient and effective, whether it be connecting patients with information or helping providers with diagnosis or treatment.

“While WHO is enthusiastic about the appropriate use of technologies, including LLMs, to support healthcare professionals, patients, researchers and scientists, there is concern that caution that would normally be exercised for any new technology is not being exercised consistently with LLMs,” the organization said. “This includes widespread adherence to key values of transparency, inclusion, public engagement, expert supervision, and rigorous evaluation.”

“Precipitous adoption of untested systems could lead to errors by healthcare workers, cause harm to patients, erode trust…

Butterfly Network shares slide on Q1 results

Butterfly Network (NYSE:BFLY) shares dropped today on first-quarter results that fell short of sales expectations.

Shares of BFLY dropped 16% to $1.88 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was relatively flat at the same time.

The Burlington, Massachusetts-based handheld ultrasound technology maker posted a loss of $33.5 million. That comes to -17¢ per share on sales of $15.5 million for the three months ended March 31, 2023.

Losses per share were 4¢ better than expectations on Wall Street. Sales were flat from the prior-year period and fell short of projections, as analysts were expecting $15.8 million in revenues.

Product revenue decreased 20% to $8.8 million, while software and other services revenue increased 45% to $6.6 million.

Operating expenses were down 24% to $44.1 million for the quarter following layoffs in August 2022 and January 2…

Navigating generative AI in drug discovery and data analysis: Seizing the opportunity and avoiding pitfalls

[Made/Adobe Stock]

Along with predictive AI, generative AI is emerging as a promising tool in drug discovery. Thanks in part to the rise of ChatGPT, interest in the technology in drug discovery is on the upswing. In March, a preprint appeared examining the potential to use generative AI to enable de novo antibody design. Also this year, the Japanese conglomerate Mitsui & Co. began working with NVIDIA to launch Tokyo-1, a project aimed at boosting Japan’s pharma industry with generative AI models. The initiative will give Japanese pharma companies and startups access to an NVIDIA DGX AI supercomputer, providing a shot in the arm to the country’s $100 billion pharma sector, which is the third largest globally.

As generative AI gains ground in pharma, businesses considering using the technology to speed up drug discovery should also take its potential drawbacks into considering. To that end, Ali Arsanjan…

How Siemens will accelerate adoption of Scopio’s AI-powered telehematology tech

Scopio’s partnership with Siemens Healthineers will “accelerate digital workflow transformation in hematology laboratories worldwide,” Scopio CEO Itai Hayut said. [Photo courtesy of Siemens Healthineers]

Scopio Labs has enlisted a huge partner to get its telehematology technology into more labs.

Scopio and Siemens Healthineers today announced a global distribution deal for the Scopio X100 and Scopio X100HT.

Siemens said those full-field digital cell morphology technology systems will complement its own Atellica HEMA 570 and Atellica HEMA 580 analyzers to give labs “high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.”

Siemens Healthineers Head of Diagnostics Sharon Bracken called the deal “a step forward in delivering automated and…

Formus Labs wins clearance for AI-powered ortho surgery planning

Formus Labs today announced FDA clearance of its Formus Hip automated radiological image processing software for hip replacement pre-op planning.

The New Zealand–founded company described the clearance as the last hurdle it needed to overcome to start making Formus Hip widely available in the United States.

According to Formus Labs, its software saves time for orthopedic surgeons so that they can consistently preoperatively plan for every case. Formus’ software combines AI and computational biomechanics to provides highly accurate outputs from scan to plan in under an hour.

“Today is a huge milestone in our journey to bring cutting-edge, pre-op surgery planning tools to surgeons, not only to make their work easier and more efficient, but also has the potential to improve the outcomes for their patients,” Dr. Ju Zhang, founder and CEO of Formus Labs, said in a news release.

“FDA clearance serves as significant validation of the accuracy and r…

10 pioneering companies implementing AI in drug discovery, development and beyond

[NicoElNino/Adobe Stock]

The pharma industry is embracing artificial intelligence (AI) to streamline drug discovery and development, although adoption remains early. The field, however, is rapidly expanding. The global AI in drug discovery market was worth about $1.1 billion last year but could grow at a 30% clip from 2023 to 2030, according to Grand View Research.

In the years to come, AI could find use to discover an array of drug targets while improving drug developers’ ability to design molecules based on fine-grained criteria. Here, we spotlight several companies exploring the use of AI in drug discovery and drug development.

1. Exscientia

Oxford, UK–based Exscientia (Nasdaq: EXAI) has pioneered AI in small-molecule drug design. The company has expanded its AI-based platform to develop novel therapeutic antibodies through generative AI design. In early 2020, the company reported the first AI-d…

Science unbound: AI and open data accelerate the pace of discovery

[Tartila/Adobe Stock]

Scientists have long been perceived and portrayed in film as old people in white lab coats perched at a bench full of bubbling fluorescent liquids. The present-day reality of scientific research is quite different from old stereotypes, with AI-driven scientific breakthroughs emerging as a major driving force behind new discoveries. Scientists are increasingly data jockeys in hoodies sitting before monitors analyzing enormous amounts of data. Modern day labs are more likely composed of sterile rows of robots doing the manual handling of materials, and lab notebooks are now electronic, in massive data centers holding vast quantities of information. Today, scientific input comes from data pulled from the cloud, with algorithms fueling scientific discovery the way bunsen burners once did.

Advances in technology and especially instrumentation, enable scientists to collect and process data at an …

Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research

Neurodegenerative disease research is witnessing significant advances. To that end, Hong Kong-headquartered Aprinoia Therapeutics is embracing a ‘precision neuroscience’ approach to neurodegeneration diagnostics. The company’s lead program, APN-1607, represents a new generation of advanced tau positron emission tomography (PET) tracers, which play a crucial role in effective and efficient diagnosis of patients suffering from neurodegenerative disorders.

Aprinoia Therapeutics’ strategy to neurodegenerative disease research focuses in part on artificial intelligence (AI) and forging strategic collaborations. Paul Tempest, the head of medicinal chemistry at Aprinoia, leads a team of experts in the field of neuroscience, AI, and pharmaceutical development. In a recent interview, Tempest explained how this multifaceted approach supports innovation in the development of novel diagnostic tools and therapies for neurodegenerative diseases.

AI in dr…

AI breakthroughs in medtech: 7 ways to enhance healthcare

[Image from Pixabay]

Whether it’s OpenAI’s ChatGPT, Microsoft’s new Bing or Google’s Bard, 2023 is the year when generative artificial intelligence entered the popular consciousness.

In the medtech space, it seems as though every company is seeking ways to incorporate some form of AI into the digital features of their products and services.

So what is artificial intelligence good at so far when it comes to advancing medtech and healthcare in general? Here are seven recent examples:

1. Helping physicians identify medical problems quickly

GI Genius’ AI-based enhancements place green boxes around areas that may need extra scrutiny during a colonoscopy, helping to prevent physicians from losing their focus. [Image courtesy of Medtronic]

Interest is growing in artificial intelligence that can help radiologists, gastroenterologists and othe…

Medtronic turns to third-party developers to boost GI Genius’ AI

The GI Genius module’s AI-based enhancements include green boxes that highlight areas that may need extra scrutiny during a colonoscopy. [Image courtesy of Medtronic]

Medtronic has turned to Nvidia to enable an AI Access platform to boost the GI Genius intelligent endoscopy module’s capabilities.

Think of a software-based business model — an app marketplace — where third-party developers create new AI tools to boost early colorectal cancer detection during colonoscopies. It’s a type of product development strategy that may become more common among medical device companies, especially as they shift toward more innovation in the digital space.

The world’s largest medtech company points to GI Genius as the first FDA-cleared, AI-assisted colonoscopy tool that helps physicians detect polyps leading to colorectal cancer. Cosmo Pharmaceuticals, GI Genius’s developer and manufactur…